RI Bio Welcomes New Board Member

Share on Social Media

RI Bio is excited to announce that Dom Messerli, President & CEO at Lenoss Medical, LLC, has been appointed to the board of directors

“We are so pleased to have Dom Messerli join us as our newest board member at RI Bio,” said Carol Malysz, executive director of RI Bio. “As an entrepreneur and founder of a RI-based medical device company, Dom will bring his successful track record and expertise in the medical device field to our board and all of our RI Bio members.”

Dom started his career in 1994 with Synthes Spine and later moved to Johnson & Johnson in 2012 where he directed the U.S. and Swiss Product Development & Marketing Groups through the merger of DePuy Spine and Synthes Spine. He founded and started up Lenoss Medical in 2016. Lenoss Medical has developed a proprietary spinal instrument and biological implant system to support the natural osseous healing process and to provide the best clinical outcomes for spinal fracture patients.

Dom graduated with a bachelor’s degree in Mechanical Engineering from Berner Fachhochschule BFH in 1993. In 2009, he completed the Wharton School’s Executive Leadership Program at the University of Pennsylvania. Dom is a 2012 graduate of the Penn State Smeal MBA Program.

Latest News

Women In Bio (WIB) Announces Launch of 14th Chapter: WIB-Connecticut

Sea Island, GA, March 03, 2021 (GLOBE NEWSWIRE) -- Women In Bio (WIB), a national organization of professionals committed to promoting the careers, leadership and entrepreneurship of women in the life sciences, is excited to announce the launch of WIB-Connecticut, the...

Top pharma industry predictions for 2021

In many ways, the beginning of 2021 isn’t just one of the most welcome New Years of the modern era — it could also be a turning point between the pre-COVID and post-COVID worlds. Perhaps more than most other industries, the landscape of pharma was radically altered by...

DRIVEN/RI-INBRE Ignition Fund FOA – DEADLINE January 11, 2021

Funding is sparse for commercial-focused biomedical projects due to their inherent risks. The DRIVEN Accelerator Hub, an NIH/NIGMS-funded consortium serving biomedical entrepreneurs in Northeast IDeA states (https://www.drivenacceleratorhub.com/), is pleased to offer...

Biotech Industry News